<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060903</url>
  </required_header>
  <id_info>
    <org_study_id>Ha03-001</org_study_id>
    <nct_id>NCT02060903</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hatchtech Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hatchtech Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy, safety and tolerability of a single
      application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the
      scalp and hair for 10 minutes at home.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of index subjects who are lice-free at all follow-up visits through to the Day 14 visit.</measure>
    <time_frame>14 days</time_frame>
    <description>The outcome is measured by lice evaluations from baseline through follow up visits.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">379</enrollment>
  <condition>Head Lice Infestation</condition>
  <arm_group>
    <arm_group_label>Abametapir Lotion 0.74% w/w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abametapir Lotion 0.74% w/w</intervention_name>
    <arm_group_label>Abametapir Lotion 0.74% w/w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Lotion</intervention_name>
    <arm_group_label>Vehicle Lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged six months of age or older.

          2. Is in good general health based on medical history.

          3. Has active head lice infestation at Screening as determined by a trained evaluator
             with the exception of the male head of household who may self-assess as being
             lice-free. Active head lice infestation is defined as at least three live lice for the
             index subject and at least one live louse for the other household members.

          4. The subject and/or their caregiver is physically able and willing to apply the
             Investigational Product at home.

          5. Belongs to a household with an eligible index subject with active head lice
             infestation.

          6. Agrees to an examination for head lice and to all visits and procedures throughout the
             study.

          7. Has signed an informed consent and/or assent form.

        Exclusion Criteria:

          1. Had treatment (over-the-counter ), home remedy or prescription medication) for head
             lice within 14 days prior to Day 0.

          2. Intends to use any other form of lice treatment from Day 0 through the Day 14 visit,
             unless provided as rescue therapy to this Protocol.

          3. Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as
             rescue therapy to this Protocol.

          4. Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling from
             Day 0 through the Day 14 visit.

          5. Has a household member(s) who is infested with lice but is not willing or not eligible
             for enrollment.

          6. Has a condition that, in the opinion of the Investigator, may increase the risk to the
             subject and/or the interpretation of the data.

          7. Has visible skin/scalp condition(s) that are not attributable to head lice
             infestation, such as an erythema score that is &gt;2, blisters, vesicles which, in the
             opinion of the investigative personnel or Sponsor, will interfere with safety and/or
             efficacy evaluations.

          8. Has eczema or atopic dermatitis of skin/scalp.

          9. Has had a prior reaction to NixÂ® or products containing permethrin.

         10. Receiving systemic or topical medication, which in the opinion of the Investigator,
             may compromise the integrity of the safety and/or efficacy assessments.

         11. Has received an investigational agent within 30 days prior to Day 0.

         12. Does not have a known household affiliation with the household members (i.e., does not
             stay in one household consistently, or sleeps at one place for several nights and then
             at another place or location).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universal Biopharma Reserach INC</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSRN Reserach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKenzie Medical Center</name>
      <address>
        <city>McKenzie</city>
        <state>Tennessee</state>
        <zip>38201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant reserach Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <disposition_first_submitted>August 25, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 25, 2015</disposition_first_posted>
  <last_update_submitted>September 9, 2015</last_update_submitted>
  <last_update_submitted_qc>September 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head Lice</keyword>
  <keyword>Hatchtech</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Mite Infestations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

